Prospective, randomized, open label trial of six vs. twelve months dual antiplatelet therapy after drug-eluting stent implantation in ST-elevation myocardial infarction.
- Conditions
- DAPT treatment after PCIDual-antiplatelettherapy after stent implantation10011082
- Registration Number
- NL-OMON39800
- Lead Sponsor
- Maasstadziekenhuis
- Brief Summary
Trial is onging in other countries
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 580
STEMI patients between 18-85 years, who underwent PCI with second generation DES implantation
Key Exclusion Criteria Enrollment: Intolerance to Aspirin, Plasugrel, Ticagrelor, Heparin, Bivaluridin, Everoliumus or Zotarolimus.
Known bleeding diathesis or known coagulopathy.
Planned elective surgical procedure necessitating interruption of dual antiplatelet therapy during the first 6 months after randomization.;Key Exclusion Criteria Randomization:
Occurrence of death, myocardial infarction, stent thrombosis and target vessel or lesion revascularization during the first 6 months after inclusion.
Stroke or bleeding requiring discontinuation of DAPT during the first 6 months after inclusion.
Oral anticoagulant therapy with coumarin derivates.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method